Clinical Studies
Ongo Weight Loss is a virtual telehealth service connecting people across all 50 states with licensed healthcare providers for personalized medical weight-management care. Your provider reviews your health history, goals, and needs to help determine which treatment options may be appropriate for you. You receive clinical guidance, prescription care when appropriate, and ongoing support throughout your journey.
Medical weight management is supported by a growing body of clinical research. Studies have evaluated medications such as semaglutide, tirzepatide, and liraglutide across different populations, treatment durations, and health conditions. The studies below are provided as educational resources and represent published clinical research. Individual study results do not guarantee the same outcomes for every person.
Published by: New England Journal of Medicine, 2021
A 68-week randomized trial of 1,961 adults evaluating once-weekly semaglutide 2.4 mg alongside lifestyle intervention. The study found substantially greater weight loss with semaglutide compared with placebo.
Read StudyPublished by: New England Journal of Medicine, 2022
A 72-week phase 3 trial involving 2,539 adults with obesity or overweight and a weight-related condition. Tirzepatide produced substantial weight reduction across the studied doses compared with placebo.
Read StudyPublished by: Nature Medicine, 2022
A two-year randomized trial evaluating semaglutide 2.4 mg alongside lifestyle intervention. The study found sustained weight reduction through 104 weeks, providing longer-term evidence on semaglutide treatment.
Read StudyPublished by: JAMA, 2024
An 88-week randomized trial examining continued tirzepatide treatment after an initial treatment period. Continued treatment maintained and increased weight reduction, while participants switched to placebo experienced substantial weight regain.
Read StudyPublished by: JAMA, 2022
A 68-week randomized clinical trial comparing weekly semaglutide with daily liraglutide in adults with overweight or obesity without diabetes. Semaglutide resulted in greater average weight reduction than liraglutide.
Read StudyPublished by: New England Journal of Medicine, 2015
A 56-week randomized trial involving 3,731 adults evaluating liraglutide 3.0 mg alongside lifestyle intervention. The study found greater weight loss with liraglutide compared with placebo.
Read StudyPublished by: New England Journal of Medicine, 2023
A large cardiovascular outcomes trial involving 17,604 adults with established cardiovascular disease and overweight or obesity without diabetes. The study evaluated whether semaglutide reduced the risk of major cardiovascular events.
Read StudyPublished by: New England Journal of Medicine, 2022
A 68-week randomized trial involving 201 adolescents with obesity. Semaglutide combined with lifestyle intervention produced greater reductions in BMI and body weight compared with placebo.
Read StudyPublished by: JAMA, 2021
A 68-week randomized trial of 611 adults with overweight or obesity evaluating semaglutide 2.4 mg alongside intensive behavioral therapy and an initial low-calorie diet. Participants receiving semaglutide had greater average weight loss than those receiving placebo.
Read StudyPublished by: The Lancet, 2023
A 72-week phase 3 trial evaluating tirzepatide in adults with obesity or overweight and type 2 diabetes. Tirzepatide produced substantial reductions in body weight compared with placebo, with the greatest reduction observed at the 15 mg dose.
Read StudyPublished by: Nature Medicine, 2023
A 72-week trial evaluating tirzepatide after participants had first completed a 12-week intensive lifestyle intervention. Tirzepatide produced additional substantial weight loss and helped participants maintain more of the weight they had already lost through lifestyle intervention.
Read StudyPublished by: New England Journal of Medicine, 2024
A clinical trial evaluating tirzepatide in adults with obesity and moderate-to-severe obstructive sleep apnea. The study found improvements in sleep-apnea severity and body weight compared with placebo, adding evidence on the potential health effects of weight reduction beyond body weight alone.
Read StudyPublished by: New England Journal of Medicine, 2024
A 68-week randomized trial evaluating semaglutide in adults with obesity and knee osteoarthritis. The study examined changes in body weight and knee-related symptoms and physical function, providing evidence on weight management in people living with obesity and knee osteoarthritis.
Read StudyPublished by: New England Journal of Medicine, 2023
A 52-week randomized trial involving 529 adults with obesity and heart failure with preserved ejection fraction. Semaglutide was associated with greater weight loss, improvements in heart-failure-related symptoms and physical limitations, and improved exercise capacity compared with placebo.
Read StudyPublished by: New England Journal of Medicine, 2024
A 52-week randomized trial evaluating semaglutide 2.4 mg in adults with obesity, heart failure with preserved ejection fraction, and type 2 diabetes. The study found greater improvements in heart-failure-related symptoms, physical limitations, and body weight compared with placebo.
Read StudyPublished by: New England Journal of Medicine, 2016
A 104-week cardiovascular outcomes trial involving 3,297 adults with type 2 diabetes at elevated cardiovascular risk. The study found that the rate of cardiovascular death, nonfatal heart attack, or nonfatal stroke was lower with semaglutide than with placebo.
Read StudyPublished by: New England Journal of Medicine, 2025
A 72-week phase 3b trial directly comparing tirzepatide with semaglutide in adults with obesity without type 2 diabetes. The study evaluated differences in body-weight reduction and cardiometabolic outcomes between the two medications.
Read Study
Clinical trials provide valuable evidence about how a treatment performed in specific study populations and under defined conditions. However, clinical research reflects outcomes observed across groups of participants and cannot predict exactly how an individual will respond.
Results may vary based on factors such as medical history, health conditions, current medications, treatment dose, duration of treatment, lifestyle factors, and other individual circumstances.
The information in this research library is provided for educational purposes only. It summarizes findings from published clinical research and is not intended to diagnose, treat, cure, or prevent any disease or condition. It does not replace individualized medical advice or establish that a particular treatment is appropriate for you.
Talk with a qualified healthcare professional to determine whether a treatment may be appropriate for your individual health needs and circumstances.
Talk to a Licensed ProfessionalFrequently Asked
These answers explain what the studies on this page can and cannot tell you. They are educational and do not replace a conversation with a licensed provider.
Clinical trials provide valuable evidence about how a treatment performed in specific study populations and under defined conditions. Clinical research reflects outcomes observed across groups of participants and cannot predict exactly how an individual will respond.